News | January 18, 2022
Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
The hospital has recently launched Radionuclide therapy
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Effectiveness of Covaxin against the Omicron variant is currently being studied
Subscribe To Our Newsletter & Stay Updated
